Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.

Vivo’s Three Fund Vehicles

Private Equity

Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Our growth capital investments help our portfolio companies accelerate revenue ramp or fund product development to drive value creation. Our private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. We invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China.

Public Equity

Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.

Venture Capital

Vivo Innovation Fund (i.e., Vivo PANDA Fund) focuses on investing in venture stage companies with the potential to develop game changing healthcare technologies or products. The fund typically invests in early stage (i.e. Series A) financing rounds.

Our Team

Our Portfolio


RareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication

Go to Top